Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBS amino acid formulation refers to a **proprietary amino acid-based formulation platform** developed by Entrinsic Bioscience rather than a single well-defined pharmaceutical active ingredient. Publicly available descriptions indicate that Entrinsic has developed patented, selective amino acid blends intended to improve intestinal barrier function, nutrient absorption, and electrolyte and fluid uptake, including an amino acid-based oral rehydration solution concept described as AA-ORS. Reported proposed effects include enhancement of villus structure, reduction of epithelial anion channel activity, and improved net intestinal absorption without relying on glucose. The program appears to have been explored in gastrointestinal and hydration-related settings such as infectious diarrhea, diarrhea-predominant irritable bowel syndrome, exercise or heat stress associated gut permeability, and oncology supportive care formulations, but the exact ingredient composition and a single standardized product identity for the queried term are not clearly disclosed in the available sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EBS amino acid formulation.